These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21074436)

  • 41. Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
    Hodgetts KJ; Ge P; Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Kieltyka A; Horvath RF; Kehne JH; Krause JE; Maynard GD; Hoffman D; Lee Y; Fung L; Doller D
    J Med Chem; 2011 Jun; 54(12):4187-206. PubMed ID: 21618986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW
    J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
    Gehlert DR; Shekhar A; Morin SM; Hipskind PA; Zink C; Gackenheimer SL; Shaw J; Fitz SD; Sajdyk TJ
    Eur J Pharmacol; 2005 Feb; 509(2-3):145-53. PubMed ID: 15733549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y
    Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
    Taché Y; Martinez V; Million M; Maillot C
    Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.
    Kojima T; Mochizuki M; Takai T; Hoashi Y; Morimoto S; Seto M; Nakamura M; Kobayashi K; Sako Y; Tanaka M; Kanzaki N; Kosugi Y; Yano T; Aso K
    Bioorg Med Chem; 2018 May; 26(9):2229-2250. PubMed ID: 29459145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.
    Takahashi Y; Hibi S; Hoshino Y; Kikuchi K; Shin K; Murata-Tai K; Fujisawa M; Ino M; Shibata H; Yonaga M
    J Med Chem; 2012 Jun; 55(11):5255-69. PubMed ID: 22587443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
    Gannon RL; Millan MJ
    Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.
    Fleck BA; Hoare SR; Pick RR; Bradbury MJ; Grigoriadis DE
    J Pharmacol Exp Ther; 2012 May; 341(2):518-31. PubMed ID: 22357972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM; Py-Lang G; Higelin J; Fischer C; Wright MB; Huber G
    J Pharmacol Exp Ther; 2001 Jan; 296(1):113-20. PubMed ID: 11123370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Corticotropin-releasing factor, urocortin 1, and their receptors in the mouse spinal cord.
    Korosi A; Kozicz T; Richter J; Veening JG; Olivier B; Roubos EW
    J Comp Neurol; 2007 Jun; 502(6):973-89. PubMed ID: 17444496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of interaction between etifoxine and CRF1 and CRF2 receptors in rodents.
    Verleye M; André N; Gillardin JM
    Neurosci Res; 2006 Sep; 56(1):53-60. PubMed ID: 16769145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
    Di Fabio R; St-Denis Y; Sabbatini FM; Andreotti D; Arban R; Bernasconi G; Braggio S; Blaney FE; Capelli AM; Castiglioni E; Di Modugno E; Donati D; Fazzolari E; Ratti E; Feriani A; Contini S; Gentile G; Ghirlanda D; Provera S; Marchioro C; Roberts KL; Mingardi A; Mattioli M; Nalin A; Pavone F; Spada S; Trist DG; Worby A
    J Med Chem; 2008 Dec; 51(23):7370-9. PubMed ID: 18989952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
    Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
    Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1.
    Bhattacharya S; Subramanian G; Hall S; Lin J; Laoui A; Vaidehi N
    J Comput Aided Mol Des; 2010 Aug; 24(8):659-74. PubMed ID: 20512399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of 4-chloro-2-(2,4-dichloro-6-methylphenoxy)-1-methyl-7-(pentan-3-yl)-1H-benzimidazole, a novel CRF
    Mochizuki M; Kojima T; Kobayashi K; Kotani E; Ishichi Y; Kanzaki N; Nakagawa H; Okuda T; Kosugi Y; Yano T; Sako Y; Tanaka M; Aso K
    Bioorg Med Chem; 2017 Mar; 25(5):1556-1570. PubMed ID: 28174066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors.
    Hummel M; Cummons T; Lu P; Mark L; Harrison JE; Kennedy JD; Whiteside GT
    Neuropharmacology; 2010 Sep; 59(3):160-6. PubMed ID: 20470804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.
    Vaughan J; Donaldson C; Bittencourt J; Perrin MH; Lewis K; Sutton S; Chan R; Turnbull AV; Lovejoy D; Rivier C
    Nature; 1995 Nov; 378(6554):287-92. PubMed ID: 7477349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.